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Background: Completion lymph node dissection (CLND) is the gold standard treatment for patients with a positive
sentinel lymph node (SLN) biopsy. Considering the morbidity associated with CLND it is important to identify
histological features of the primary tumor and/or of SLN metastasis that could help to spare from CLND a subset of
patients who have a very low risk of non-SLN metastasis. The objective of this study is to identify patients with a
very low risk to develop non-SLNs recurrences and to limit unnecessary CLND.
Methods: A retrospective long-term study of 80 melanoma patients with positive SLN, undergone CLND, was
assessed to define the risk of additional metastasis in the regional nodal basin, on the basis of intranodal
distribution of metastatic cells, using the micro-morphometric analysis (Starz classification).
Results: This study demonstrates that among the demographic and pathologic features of primary melanoma and
of SLN only the Starz classification shows prognostic significance for non-SLN status (p<0.0001). This parameter was
also significantly associated with disease-free survival rate (p<0.0013).
Conclusion: The Starz classification can help to identify, among SLN positive patients, those who can have a real
benefit from CLND. From the clinical point of view this easy and reliable method could lead to a significant
reduction of unnecessary CLND in association with a substantial decrease in morbidity. The study results indicate
that most of S1 subgroup patients might be safely spared from completion lymphatic node dissection.
Furthermore, our experience demonstrated that Starz classification of SLN is a safe predictive index for patient
stratification and treatment planning.
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The sentinel lymph node (SLN) is the first lymph node
reached by metastasizing cancer cells from a primary
tumor. The lymphatic metastasis in melanoma always
proceed sequentially involving cancer cell spreading from
the primary site to regional nodes then to distant sites. In
1992 Morton et al. have demonstrated that it is rare that
melanoma cells skip the sentinel lymph node and meta-
stasize in other nodes [1]. Consequently, since its intro-
duction into clinical practice, SLN biopsy has become a
widely accepted procedure for predicting the status of re-
gional lymph nodes [2,3]. The presence of SLN metastases* Correspondence: migliano@ifo.it
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reproduction in any medium, provided the oris the strongest prognostic factor for melanoma and the
histological status of the sentinel node has repeatedly
shown to provide excellent prognostic information with
respect to cancer spreading, disease–free and overall sur-
vival rate [4]. Current standards of practice suggest com-
pletion lymphatic node dissection (CLND) for all the
patients with a positive SLN, whereas patients with nega-
tive SLN are considered to be at lowest risk of further
lymph node extension. CLND aims to increase the local
control of disease, survival improvement as well as staging
patients. However, several studies have also demonstrated
that only 20% of patients with a positive SLN will have fur-
ther (Non-SLN) metastasis at CLND [5,6]. Although the
impact of early dissection of subclinical micrometastatic
nodes is well documented on the overall survival rate [7-9],
most of the patients don’t present nodal involvement.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(paresthesias, wound infection, seroma and lymphoedema)
it will be important to identify histological features of the
primary tumour and/or of SLN metastases that could help
to spare from CLND a subset of patients who are unlike to
have metastatic non-SLNs and thus will not take any bene-
fit from further nodal dissection.
The Starz classification is a micromorphometric analysis
of the SLNs based on two parameters: the number of SLN
slices, that contained melanoma cells, and the maximum
depth of cellular invasion, measured as the maximum dis-
tance in millimetres between intra-nodal tumour cells and
the inner margin of SLN capsule [8].
Our study was designed to define the risk of additional
metastasis in the regional nodal basin on the basis of SLN
micro-morphometric study, in order to identify patients
with the lowest risk of tumour metastasis in NSLNs. More-
over, we retrospectively evaluated the disease-free survival
(DFS) rate and the overall survival (OS) rate of patients,
considering several clinical and pathological aspects of
primary melanoma compared with the findings of micro-




Between 2000 and 2005, 537 consecutive patients with
primary cutaneous melanoma that underwent to SLN biop-
sies were identified from a prospectively maintained depart-
mental database comprising 685 patients. Among these,
100 SLN positive patients (18.6%) subsequently undergone
to CLND were initially enrolled for this study. However, the
availability of the original specimens for histopathologic re-
examination and a full documented post-operative period
(at least five years) restricted the patient group to 80 sub-
jects. All data from patients undergone sentinel lymph node
biopsy, regardless of gender, age and localizations were
retrieved from the pathology database of Dept. of Plastic
Surgery and of the Dept. of Dermatopathology of the “Der-
matological Institute San Gallicano” of Rome, comprising
more than 900 patients from a 13-years period (1997–
2010). To obtain a full post-operative period of at least five
years we selected 80 subjects showing positive SLN treated
between 2000 and 2005. Most patients were followed in the
Departments of Plastic Surgery and the data concerning
their evolution were available in their medical records. For
those who interrupted their follow-up, the physician in
charge of follow-up was interviewed systematically to get
the latest status. Survival was calculated from the date of
the initial excision of the primary tumor.
SLN procedure
All patients underwent preoperative lymphoscintigraphy
to ascertain the number and location of regional nodalbasins at risk for metastatic disease. The lymphoscin-
tigraphy was performed the day before or the same day
of surgery by intradermal injection of technetium-99-
labeled nanocolloid. Under a general anaesthesia or neu-
roleptanalgesia, blue patent V (0.5-1 ml) was injected
intradermally around the excisional scar. Sentinel lymph
nodes were identified intraoperatively by their blue
colour and radioactivity detected with hand-held gamma
probe. All blue nodes and all radioactive nodes (hottest)
were considered sentinel and were removed. All patients
presenting a positive SLN underwent within four weeks
to a CLND.
Histopathological examination
SLNs were fixed in 4.5% formaldehyde for 24 hours. Then
three-dimensional measurement and macroscopic charac-
teristics were evaluated for every lymph node. Lymph
nodes were cut parallel to the longest axis into slices about
1 mm thickness and embedded in paraffin blocks. Four
sections (3 μm thick) of each slice were produced with a
microtome: the first one was stained with haematoxylin-
eosin, and the subsequent for the immuno-hystochemistry
with S100, HMB45 and MART1 antibodies [9,10].
Starz staging
According to the Starz classification [8,11,12] all patients
were divided into three categories based on the number
of positive sections (n) and the maximum distance from
the interior margin of the biggest metastatic group to
the capsule of the SN (d) as follows: S1 for peripheral in-
volvement (1<n<2 and d <0.3 mm), S2 for extended or
multifocal involvement (n>2 and 0.3<d<1 mm) and S3
classifying metastatic invasion deeper than 1 mm below
the capsular level (d>1 mm) [8,11,12].
Statistical analysis
An independent biostatistician performed statistical evalu-
ation. Patient’s characteristics included: demographic data
(age and sex) and histological features of the primary mel-
anoma (Breslow thickness, Clark level, ulceration and histo-
logical subtype); while for the sentinel lymph node included
the number of sentinel lymph node removed, the pattern of
invasion and the invasion depth of metastatic cells in the
sentinel lymph node (Starz Classification). For statistical
analysis parametric tests were applied: Hazard Ratio and
95% Confidence Interval were used to study the test and
overall survival rate. Kaplan-Meier curves were used to esti-
mate significance in OS differences. Significance for all stat-
istical tests was defined as p values <0.005.
Results
In this study we have enrolled 80 patients, 46 (57%)
were males and 34 (43%) were females (mean age 48
years; range of 20–83 years). The mean Breslow
Figure 1 Kaplan-Meier survival curve for patients undergoing successful CLND. The ten-years overall survival (OS) showed a significant
shorten survival in SLN-positive patients than in SLN-negative patients (p<0.0001). Mean survival time (8.01±0.44 yrs for SLN+ and 9.61±0.21 yrs
for SLN-).
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(range 0.4-6.0 mm); 3 patients (4%) were of Clark II,
21 (26%) were of Clark III, 52 (65%) were of Clark
IV and 4 (5%) of Clark V. Melanoma subtype in-
cluded nodular (36%), superficial spreading (47%),
and polypoid (17%). More than half of the tumors
were ulcerated (51%). Regarding the regional distri-
bution of SLN biopsies 36 were axillary (45%), 32
groin (40%), 8 (10%) present a double basin (7axillary
+groin and 1 axillary+supraclavear), and 4 of the
neck (5%). CLND found at least one positive non-
SLN in 15 cases (19%). The median follow-up was 78
months (range 60–120 months). During the follow-
up period only 5 patients (6%) had a loco-regionalTable 1 Results for number of excised SLN




>3 9 11%recurrence. From the 80 enrolled cases, 69 (86%)
were alive without evidence of disease at the time of
this writing. According with the literature, Kaplan
Meier curve, used to evaluate overall survival (OS),
showed a significant shorten survival in SLN-positive
patients than in SLN-negative patients (p<0.0001;
chi-square test) (Figure 1). To better analyze the
data, patients were divided according to the number
of lymph nodes excised after finding micro-
morphometric metastasis in SLN. In particular, in 9
patients (11%) were excised only one lymph node, in
24 patients (30%) were excised two lymph nodes, in
38 patients (48%) were excised three lymph nodes
while in 9 (11%) were excised more than 3 lymphTable 2 Results for number of positive SLN





Table 3 Results of S-classification for patients in this
study
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the number of positive NSLNs: 47 patients (59%)
presented one positive lymph node, 15 patients (19%)
two positive lymph nodes, 12 patients (15%)
presented 3 positive lymph nodes whereas for 6 pa-
tients (7%) the positive lymph nodes were more than
3 (Table 2).
Regarding the Starz classification we found that 40 pa-
tients (50%) were classified as S1, 15 (19%) as S2 and 25
(31%) as S3 (Table 3). In patients without NSLNs in-
volvement, 40 SLNs (61%) were classified as S1, 9 (14%)
as S2, while 16 SLNs (25%) were classified as S3. On the
other hand, in NSLNs with metastasis, we reported 9
SLNs (60%) were classified as S3 and 6 SLNs (40%) were
classified as S2. None of the 40 patients of the S1 group
presented NSLN metastasis. The occurrence of at least
one melanoma-positive non-SLN significantly increased
from 0 (of 40 in S1 SLNs) to 6 (of 15 in S2 SLNs) up to
9 (of 25 in S3 SLNs) (p=0.0124; chi-square test). More-
over, it is important to highlight that among the parame-
ters studied the univariate analysis indicated a significant




male 39 60% 7







N of positive SLN
1 46 71% 1
>1 19 29% 2
STARZ CLASSIFICATION
S1 40 61% 0
S2 9 14% 9
S3 16 25% 6classification (p<0.0001; chi-square test) (Table 4). The
mean Breslow thickness was 2.6 mm for S1 group, 2.8 mm
for the S2 group, and 3.9 mm for the S3 group. The
highest percentage of ulcerated primary tumor was found
in the S3 patients group (S1 56%, S2 40%, S3 83%).
Concerning the distribution of melanoma subtypes we
found: in the S1 group 24 of 40 (60%) were SSM, 11 of 40
(27.5%) nodular and 5 of 40 (12.5%) polypoid; in the S2
group 8 of 15 (54%) were SSM, 5 of 15 (33%) nodular, 2 of
15 (13%) polypoid; in the S3 group 4 of 25 (16%) were
SSM, 14 of 25 (56%) nodular and 7 of 25 (28%) polypoid.
Distant metastasis were present in 2 patients S1 (5%), in 2
patients S2 (13%) and in 2 patients with S3 (8%). S-
classification results are summarized in Table 5. The uni-
variate analysis of disease-free survival (DFS) showed no
significant association with the variables considered in the
study (sex, age, Breslow thickness, and number of positive
SLNs) with the exception of S-classification (OR 7.4 [95%
CI 1.94, 28.24]; p=0.013; chi-square test) (Table 6). The
overall OS rate was 86%, among the 11 patients dead we
observed the following distribution: in the S1 group 3 of
40 patients (7,5%), in the S2 group 2 of 15 patients (13%),
and in the S3 group 6 of 25 patients (24%). The OS ana-
lysis showed significant association only with the Breslow
thickness (OR 3.08 [95% CI 0.75, 12.61]; p=0.002)
(Table 7).
Discussion
Negative SLN biopsy findings are well known prognostic
factors. Other ways, the positivity to a SLN biopsy lead the
patient to a completion lymph node dissection (CLND)mber of positive lymph nodes and S‐classification
Disease-positive CLND (n=15) univivariate analysis












Table 5 Tumour characteristics of 80 patients with cutaneous melanoma who underwent CLND divided according to
the S-classification
Histologic type
S-group Ulceration % Breslow (mm) SSM % Nodular % Polipoid % CNLD + % Distal Mestastasis % Death
S1 56% 2.6 60% 27.5% 12.5% 0% 5% 7.5%
S2 40% 2.8 54% 33% 13% 40% 13% 13%
S3 83% 3.9 16% 56% 28% 36% 8% 24%
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die within 5 years [13-15]. Morton et al. demonstrated a
highly significant survival benefit in SLN-positive patients
who had received CLND (5-year survival rate 72%) com-
pared to SLN-positive patients who had received delayed
ELND (Elective LND) after clinical detection of lymph
node metastasis (5-year survival rate 52%) [16].
However, at the moment, there is no consensus on the
benefit of a completion dissection in melanoma patients.
As reported in literature, only the 14%-18% of positive
patients will harbour further disease in the affected basin
[14-17]. Only patients with secondary involvement in
NSLNs find benefit in a CLND while a large percentage
of patients (NSLNs negative) will increase only the mor-
bidity rate due to this surgical procedure [18]. In this
respect it will be of primary importance to identify histo-
logical biomarkers (relative to patient, tumour, and SNL
characteristics) that can safely predict an additional risk
of NSLN recurrence in SLN positive patients. In this
way we will be able to increase the disease-free survival
and the overall survival rate lowering at the same time
the morbidity rate. In our opinion the key point would
be to recommend CLND only to those patients who
have an high predictive risk of NSLN positivity, using
a patient selection criteria as currently stated in the
treatment of breast cancer, where patients with sub-Table 6 Disease free survival analysis
DISEASE-FREE SURVIVAL RATE
HR 95% C.I. P value
SEX
Male 1
Female 3.28 0.366-29.455 0.288
Age(Y)* 1.004 0.950-1.062 0.874
Breslow (mm)* 3.16 0.678-11.517 0.081
No positive SLN
1 1
>1 1.672 0.279-10.006 0.54
STARZ CLASSIFICATION
S1 1
S2-S3 7.4 1.938-28.244 0.0013
C.I. confidential interval, HR Harzard ratio, *as continuous variable.micrometastasis (< 0.2 mm) in the SLN are spared from
axillary CLND, due to the very low risk of nodal recur-
rence [19-22]. In melanoma the Breslow thickness and
the ulceration of the primary tumour, the number of
positive SLNs and tumour penetrative depth inside the
SLN are significant prognostic factors of high risk
NSLNs positivity [14,15,22-26]. However, statistical data
reviewed from the literature on these factors are still
very poor so that currently none of these parameters can
give a safe a reliable prognostic indication on NSLNs
status. Previous studies have shown that several charac-
teristics of deposits of metastatic melanoma in SLNs
correlate with the presence of tumour in NSLNs in sub-
sequent CLND specimens [17,21-24]. In our study, the
microanatomic features of the SLNs metastasis, particu-
larly the tumour penetrative depth of the deposit
(according with Starz classification) and several clinic-
pathologic data were analyzed looking for a predictive
marker for NSLN involvement. Among 80 cases under-
went CLND, 15 patients (19%) had NSLN positivity,
while the remaining 65 (81%) had no metastases,
according to the data reviewed from the literature
[13,14,18,27-30]. Patients presenting a positive CLND
were all classified as S2 or S3 at the SLN histological
micro-morphometric analysis confirming that Starz clas-
sification is an indicative factor of high risk of regionalTable 7 Overall survival analysis
OVERALL SURVIVAL RATE
HR 95% C.I. Pvalue
SEX
Male 1
Female 1.692 0.588–4.867 0.33
Age(Y)* 1.02 0.986–1.055 0.244
Breslow(mm)* 7.42 2.031–27.119 0.002
No Positive SLN
1 1
>1 1.727 0.576–5.179 0.33
STARZ CLASSIFICATION
S1 1
S2-S3 3.083 0.753–12.613 0.104
C.I. confidential interval, HR Harzard ratio, *as continuous variable.
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ation of “median primary tumour thickness” factor
resulted, in our study, not statistically significant (p
value=0.7436) on NSLNs metastasis, but well correlated
to the OS (overall survival rate - Table 7; p value=0,02).
The predictive value of “tumour ulceration” factor on
NSLN involvement has been found in some previous
studies, but not confirmed by others, thus indicating a
great deal of variability which limits the drawing of def-
inite conclusions [31-38]. In our study, the ulceration of
primary lesion was present in 41 patients (51%). Evaluat-
ing ulceration factor in S-subgroups 56% of S1, 40% of
S2 and 83% of S3 patients had ulcerated lesions. Among
the 11 patients who died for melanoma metastasis the
ulceration factor was present in 9 (81%). It is interesting
to note that inside the group of died patients 6 (55%)
were classified as S3, 2 (18%) as S2 and 3 (27%) as S1.
The analysis of S1 dead patients revealed that everyone
presented peculiar characteristics: one patient had two
different SLN compromised, another patient presented
severe ulceration of the primary lesion, while the third
patient had an high Breslow thickness, nodular type, pri-
mary melanoma. These results outline the relevance of
clinical biomarkers that can be useful, in correlation to
the histological markers, to predict S1 patients clinical
outcome. It should be reported, that Reeves et al. [26]
proposed the ratio size of metastases on SLN/ulceration
(S/U score) as predictor factor of NSLNs status, while
Frankel et al. [27] utilized the relation between the thick-
ness of primary tumour and the surface area, measured
in percentage, of the metastases on SLN.
According with previous studies [2,14,16,17,27] and
the recent study of Nagaraja [38], where it is shown a
very accurate and extensive meta-analysis involving sev-
eral predictive factors to determine the risk of lymph
node metastasis, our data confirmed that about 20% of
SLN positive patients undergone CLND present an add-
itional lymphatic involvement. At the moment, according
to the staging guidelines of the American Joint Committee
on Cancer (AJCC) the most important prognostic factor in
patients affected by melanoma is the SLN status [28-31].
The current standard treatment for SLN positive patients
is the completion lymphatic node dissection. Within the
last few years, several studies have been conducted to de-
termine whether some patients could be classified as low
risk of further nodal metastasis according to the type of in-
volvement of the SLN. Furthermore, the overall data pub-
lished [11,16,21,29] and the present study evidenced that
the prognosis of patients is determined not only by the
presence of melanoma cells in SLNs but also by a micro-
morphometric characterization of SLNs according to the
Starz classification. On these bases some Authors sug-
gested the possibility to avoid the CLND to a subgroup of
selected patients [30-34]. Already in few centres, patientswith SLN tumour deposits <0.1mm in maximal dimension
can choose if undergo CLND or clinical nodal follow-up
[16,18,33-38]. In our report, using univariate analysis, we
confirmed the prognostic relevance of Starz classifica-
tion suggesting that patients classified as S1 could safely
spare to the CLND. None of S1 patients presented
CLND positivity, suggesting that the increased morbid-
ity associated with complete nodal dissection could be
avoided in this group of patients. Moreover, the DFS of
S1 patients was significantly higher than S2-S3 patients
(p value 0.0013).
In conclusion, our results showed that, among the 80
SLN positive melanoma patients studied, 65 (81%) under-
went to CLND in absence of an evident benefit but in-
creasing only the morbidity. NSLNs metastases were
found only in 15 patients (19%). None of the S1 patient
had positive NSLN. Considering that we recorded three
dead patients among the S1 subgroup in absence of NSLN
involvement, our future study will aim to select important
biomarkers that, in combination with S-classification,
could help to select a S1 subgroup presenting major risk
of disease progression. Interestingly, while this research
was in progress, Veenstra et al., reported a positive 5-years
experience for 16 melanoma patients classified as Starz
level 1 that did not undergo completion lymphatic node
dissection [33]. Although further investigations are
needed, on larger and multicentric studies, we think that
our observations can contribute to suggest the way to find
a clinically reliable technique (i.e. an algorithm of the
mentioned factors), and an easy application method to
identify, among melanoma patients, those who present
the higher risk of NSLN recurrence [37,38]. In our opin-
ion this selection will provide a more accurate depiction
of prognosis and will help to define subsequent recom-
mendations for the treatment and the follow-up care.
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